

REMARKS

Claims 2, 6, 10, 11, and 13-31 were allowed on November 18, 2009. On January 28, 2010 the Examiner mailed a communication requesting that the dependency of claim 13 (original claim 21) be corrected because it depends on a cancelled claim. Claims 2, 6, 11, 20, and 21 are currently amended to correct informalities (i.e., claim dependencies, etc.), that were agreed to by the Examiner on February 18, 2010 during a telephone conversation with Applicants' attorney.

No new matter is added.

Upon review, Applicants' note that claim 13 is an independent claim so it is not clear what error the Examiner was specifically referring to. However, Applicants' have noted several informalities in the claims that require correction, and thus have made the following amendments:

Claim 2 has been amended to delete the superfluous reference to formula II and III from the proviso.

Claim 6 has been amended to delete the superfluous definition of "Ar" and to correctly refer to the identified formula IV structure as such in the proviso.

Claims 11 and 20 have been amended to change to their dependency from cancelled claim 1 to claim 2.

Claim 21 has been amended to change to its dependency from cancelled claim 5 to claim 6.

CONCLUSION

In view of the amendments made herein, Applicants' respectfully submit the application is in proper condition for issuance and request their entry.

Respectfully submitted,

Date: February 18, 2010

Pfizer Inc
Patent Dept., 150-5-49
235 East 42nd Street
New York, NY 10017-5755
(212) 733-4827

/Jason G. Tebbutt/
Jason G. Tebbutt
Attorney for Applicant
Reg. No. 55,671